Results 141 to 150 of about 721 (165)

A Dose‐Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers

Clinical Pharmacology in Drug Development, 2022
Kazuo Umemura
exaly  

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury

Cancer Chemotherapy and Pharmacology, 2021
Malte von Bonin
exaly  

Glucarpidase

2020
openaire   +1 more source

Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients

Leukemia and Lymphoma, 2021
Florent Puisset, Loic Ysebaert, Etienne Chatelut   +2 more
exaly  

Use of glucarpidase in high-dose methotrexate-induced nephrotoxicity

High-dose methotrexate (HD-MTX) is an important component in the treatment of a variety of childhood and adult cancers. Although HD-MTX is safely administered to most patients, it may lead to significant toxicity. Many factors could be involved in the toxic effect of HD-MTX: a) drug-drug interactions.
Donzelli Livia, Minotti Clara
openaire   +1 more source

Glucarpidase receives additional reimbursement

PharmacoEconomics & Outcomes News, 2012
openaire   +1 more source

Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance

Oncologist, 2018
Kjeld Schmiegelow, W Archie Bleyer, Anushree Shirali   +2 more
exaly  

Glucarpidase

2018
openaire   +1 more source

Glucarpidase: Treatment for toxic MTX concentrations

Pharmacy Today, 2012
openaire   +1 more source

Glucarpidase

Stephanie J. Phelps, Tracy M. Hagemann, Kelley R. Lee   +2 more
openaire   +1 more source